Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Prague: Battleground in the Fight Against Retinal Diseases

November 2, 2012

LUGANO, Switzerland, November 2, 2012 /PRNewswire/ –

12th International AMD and Retina Congress in Prague, 2-3 Nov 2012

ESASO, the European School for Advanced Studies in Ophthalmology, has opened the 12th
AMD and Retina Congress in Prague. Following on from the 11th congress in Lisbon, which
covered the whole spectrum of retinopathy, this year’s meeting in the Czech Republic takes
a significant step forward, demonstrating how international collaboration and exchange
among ophthalmologists can facilitate therapeutic advancements. ESASO expects around 1000
delegates from 40 countries. Twenty-three plenary presentations are planned with 20 case
studies, six meet-the-expert-sessions as well as panel discussions and a poster
exhibition.

The first session, will be chaired by Prof. Anat Loewenstein from the Tel Aviv Medical
Center and Prof. Frank Holz from the University of Bonn, who will review therapeutic
approaches to the treatment of retinal vein occlusion (RVO). In particular, this session
will discuss the evidence for intravitreous aflibercept which has the potential to offer
new treatment options for patients with RVO.

A second session focuses on surgical treatment of macular diseases and will be chaired
by Prof. Anselm Kampik from the Ludwig Maximillians University in Munich and Michael
Georgopoulos from the Medical University of Vienna and the Vienna Medical Hospital. During
this session, the Faculty will discuss the role of surgical treatments in the management
of patients with diabetic macular edema (DME). An additional focus will be the challenges
and impact of cataract surgery in patients with AMD and diabetic retinopathy.

Expanding the role of anti-VEGF therapy in ocular disease: examining the evidence, is
the title of the session to be led by Prof. Leonidas Zografos, Chairman at the Faculty of
Biology and Medicine of the University of Lausanne and Prof. Gabriel Coscas from the
Creteil University Eye Clinic at the University of Paris XII. The session will cover a
controversial issue: the role of anti-VEGF therapy in the field of ocular tumours.

With 366 million people worldwide predicted to have diabetes by 2030, the treatment of
diabetic retinopathy is a key clinical challenge, and will be the subject of the session
chaired by Prof. Paul Michell from the University of Sydney and Dr. Susan B. Bressler from
the Johns Hopkins University School of Medicine in Baltimore. Leading retina specialists
will discuss a new system for the classification of DME. This system facilitates
innovative treatment paradigms that minimise the risk of moderate visual loss, including
the approval of the anti-VEGF agent ranibizumab. In a roundtable discussion a faculty of
experts will address a variety of topics on the management of DME, ranging from the role
of wide-field angiography and OCT, to systemic management.

A further session is devoted to the management of neovascular AMD; Prof. Ursula
Schmidt-Erfurth from the University of Vienna and Marco Zarbin from the New Jersey Medical
School in Newark NJ, USA will Chair this session and 12 specialists will present various
interactive clinical cases including recalcitrant vascularized PED, and the treatment of
PCV in the anti-VEGF era.

In the final session, two scientists from the Oakland University in Royal Oak, MI,
USA, Prof. Antonio Capone Jr., Clinical Professor of Biomedical Sciences and Dr. George
Williams, Chair of the department of Ophthalmology will lead a session highlighting the
disorders of the vitreomacular interface. One of the topics in this session will be to
explore whether pharmacological vitreolysis has the potential to induce total posterior
vitreous detachment without the need for surgery.

Beside this engaging scientific programme, the humanitarian award, XOVA, will be an
integral part of the congress. XOVA is an award program led by international eye care
specialists and sponsored by Novartis Pharma and Alcon. XOVA provides funding (in the form
of a grant) to non-profit initiatives that are expected to have a significant impact on
unmet needs in ophthalmology. The 2012 XOVA award will be presented during the congress.

The ESASO Organising Committee of the 12th International AMD and Retina Congress in
Prague

Giuseppe Guarnaccia is President of the ESASO Foundation and Director III of the
Surgery Department at the BMM Hospital, Reggio Calabria.

Borja Corcostegui, Professor and Member of the ESASO Foundation Board, Founder and
Director of the Instituto de Microcirurgia Ocular (IMO), Barcelona.

Francesco Bandello, Professor and Member of the ESASO Founding Board, is Chairman of
the Department of Ophthalmology at the University Vita-Salute Scientific Institute San
Raffaele, Milan.

12th AMD Congress 2012:

http://www.esaso.org/12th-international-amd-and-retina-congress

ESASO Education 2013:

http://www.esaso.org/programme-2013

ESASO Image Brochure:

http://www.presseportal.ch/go2/ESASO_Image_Brochure

        Contact:
        ESASO
        c/o Universita della Svizzera Italiana
        Via Lambertenghi 10 A
        6904 Lugano, Switzerland

        Gariella Skala, General Manager ESASO
        Gabriella.Skala@esaso.org
        Cell: +41-76-300-90-00

SOURCE ESASO


Source: PR Newswire